06/19/2026
This is the kind of progress that gives our community hope. continue to rise. 🫁🤍✨
Thank you to Fox Chase Cancer Center and Labcorp for collaborating on a clinical trial to evaluate an ultra-sensitive blood-based test for early-stage non-small cell lung cancer recurrence risk.
For people treated with curative intent, the fear of recurrence is very real. Tools that may help detect molecular recurrence earlier, before traditional imaging or symptoms, could be a meaningful step toward more personalized follow-up, better decision-making, and improved outcomes.
This is why research, and early detection matter.
This is why lung cancer must continue to receive the urgency, innovation, and attention it deserves.
We are grateful to see lung cancer research moving forward and hopeful for what this could mean for patients and families.
Anyone with lungs can get lung cancer, and no one ever deserves it.
https://bit.ly/4egR4Td
Fox Chase Cancer Center has launched a new clinical trial collaboration with Labcorp to evaluate a blood test designed to detect signs of lung cancer recurrence earlier than traditional monitoring methods.
Led by Hossein Borghaei, DO, MS, Chief of the Division of Thoracic Medical Oncology at Fox Chase, the study will explore whether measuring circulating tumor DNA in the bloodstream can help identify recurrence risk in patients with early-stage non-small cell lung cancer.